Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 177Lu-RAD204 |
| Synonyms | |
| Therapy Description |
177Lu-RAD204 is a radioconjugate comprising the radionuclide lutetium-177 conjugated to a nanobody targeting CD274 (PD-L1), which potentially delivers beta radiation to tumor cells expressing CD7274 (PD-L1), resulting in tumor cell cytotoxicity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 177Lu-RAD204 | 177Lu RAD204|177LuRAD204 | PD-L1/PD-1 antibody 133 | 177Lu-RAD204 is a radioconjugate comprising the radionuclide lutetium-177 conjugated to a nanobody targeting CD274 (PD-L1), which potentially delivers beta radiation to tumor cells expressing CD7274 (PD-L1), resulting in tumor cell cytotoxicity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06305962 | Phase I | 177Lu-RAD204 | 177Lu-anti-PD-L1 sdAb in Metastatic Non-small Cell Lung Cancer | Recruiting | AUS | 0 |